Fig. 1

Computer tomography (CT), magnetic resonance imaging (MRI, T2 TSE) and laboratory results during the clinical course. a-d Abdominal CT and MRI before a, one month b, three months (c) and nine months (d) after treatment with ceritinib. a, b Abdominal CT and MRI showed no abnormalities of the liver. c CT showed a dilation of the intrahepatic bile duct and MRI also showed dilation of the intrahepatic bile duct with periportal edema. d CT and MRI showed a dilation of the intrahepatic bile duct and newly detected biloma. The results of serum T-Biil, ALP, γGT, CRP, IL-18 and IL-6 in the clinical course are shown under the imaging study. Serum IL-6 was decreased, but serum IL-18 was increased with the progression of the ceritinib-induced DIC even after its discontinuation and treatment with PSL